生物活性：(Rac)-Tenofovir-d6 is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV)[1].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
(Rac)-Tenofovir-d6 相关抗体:
CD4 Antibody
TARBP2 Antibody (YA1433)
SAMHD1 Antibody (YA1542)
SV40 T Antigen Antibody (YA3256)
HBcAg Antibody (YA910)
HBsAg Antibody (YA913)
CLEC12A Antibody (YA1419)
Tat SF1 Antibody (YA2886)
分子量：293.25
Formula：C9H8D6N5O4P
CAS 号：1020719-94-1
非标记 CAS：107021-12-5
性状：固体
颜色：White to off-white
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：-20°C, protect from light
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
纯度 & 产品资料
纯度： 99.82%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Murphy RA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci. 2017 Mar 1;18(3).
 [Content Brief]
[3]. Musumeci G, et al. M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017 Feb 1;7:41018.
 [Content Brief]
[4]. Wahl A, et al. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep. 2017 Feb 1;7:41098.
 [Content Brief]
[5]. Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8.
 [Content Brief]